VNVC and Sanofi break ground on vaccine and biological product plant
VOV.VN - French President Emmanuel Macron and Vietnamese Vice President Vo Thi Anh Xuan launched the groundbreaking ceremony on May 27 for a vaccine and biopharmaceutical plant, a joint project between Vietnam Vaccine Joint Stock Company (VNVC) and Sanofi, French multinational pharmaceutical and healthcare company.
The event was part of Macron’s state visit to Vietnam from May 25 to 27. This large-scale, state-of-the-art facility marks a significant milestone in the comprehensive strategic partnership between France and Vietnam in health care and biotechnology.
The plant will be built on a 26,000 m² site in the Phu An Thanh Industrial Park, Ben Luc district, Long An province, with an initial investment of around US$80 million. It is expected to begin operations by the end of 2027.
The facility will gradually receive transferred technology from Sanofi to produce high-quality, essential vaccines, catering to domestic needs at lower costs and aiming to supply regional export markets. Vaccines with high demand, particularly those protecting children and adults, will be prioritised for production.
It is designed to meet the world’s most stringent Good Manufacturing Practice (GMP) standards, including EU GMP, US FDA GMP, and WHO GMP. It will also comply with Good Laboratory Practice (GLP) and AAALAC standards for humane and safe animal research, as well as numerous advanced environmental protection and “green” and “smart factory” technologies.
Speaking at the groundbreaking ceremony, Burak Pekmezci, general director of Sanofi Vietnam, noted that the globally standardised plant would soon deliver advanced vaccines, medicines, and preventive health solutions to the Vietnamese people, with a view to improving public health and strengthening healthcare resilience.
Meanwhile, Ngo Chi Dung, chairman and CEO of VNVC, emphasised that the COVID-19 pandemic highlighted the urgent need for modern, high-capacity vaccine production facilities. With the ability to manufacture hundreds of millions of doses annually, the plant will help Vietnam secure its vaccine supply, reduce costs, and ensure equitable access for all citizens, he said.
Beyond manufacturing, the plant will host a 1,500 m² Research and Development (R&D) Centre dedicated to cutting-edge vaccine and biopharmaceutical technologies, especially mRNA platforms, which hold great promise for producing novel vaccines, including cancer treatment vaccines.
VNVC first launches pneumococcal 15-valent conjugate vaccine in Vietnam
VOV.VN - Vietnam Vaccine JSC (VNVC) began administering the pneumococcal 15-valent conjugate vaccine (PCV15 or Vaxneuvance) to both children and adults on May 8, marking the first time this advanced vaccine is available in Vietnam.
